Proteinuria

Applications of ACE Inhibitors in Non-Diabetic Proteinuria
Eric T. Pride, M.D.
ace.ppt

Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone
Harry W. Floyd, M.D.
Case Report and Lit Review.ppt

Diseases of the Kidney
Diseases of the Kidney.ppt

Nephrotic Syndrome
Nephrotic Syndrome.ppt

Preeclampsia - Eclampsia
Jack Ludmir, M.D
Preeclampsia-Eclampsia.ppt

Renal Disease: Overview and Acute Renal Failure
Jack DeRuiter, PhD
Renal Disease: Overview and Acute Renal Failure.ppt

Acute Renal Failure
Jayanti Jasti, M.D.
Acute Renal Failure.ppt

Orange Urine on Halloween
Eva Delgado, MD
Glomerulonephritis.ppt

Hypertension Control and Progression of Renal Disease
Hypertension Control and Progression of Renal Disease.ppt

Alport Syndrome
Aditya Mattoo, MD
Alport Syndrome.ppt

Adult Onset Minimal Change Disease

Nephrology Grand Rounds, Aditya Mattoo, MD
Adult Onset Minimal Change Disease.ppt

Association between HIV and renal disease
Saleem Bharmal
HIV-Associated_Nephropathy.ppt

Hematuria
Sarah Swartz, MD
Hematuria.ppt

Laboratory Evaluation of Renal Function
S .POPLI. M.D.,F.A.C.P.
Laboratory Evaluation of Renal Function.ppt

Hypertension in Pregnancy
Peter Bernstein, MD, MPH
Hypertension in Pregnancy.ppt

Proteinuria Is an Independent Risk Factor for Mortality in Type 2 Diabetes
Ahmed M. Awad, D.O.
proteinuria_reduction.ppt

Poststreptococcal Glomerulonephritis
Nirav Dhruva
Glomerulonephritis.ppt

Recurrent And De Novo GN After Renal Transplantation
GN-after-renal-transplantation.ppt

Crescentic IgAN
Aditya Mattoo
Crescentic IgAN.ppt
600 Scholarly Published articles free access

1. Progress in pathogenesis of proteinuria.
2. Cyprinus carpio Decoction Improves Nutrition and Immunity and Reduces Proteinuria through Nephrin and CD2AP Expressions in Rats with Adriamycin-Induced Nephropathy.
3. Proteinuria is associated with quality of life and depression in adults with primary glomerulopathy and preserved renal function.
4. The prevalence of immunologic injury in renal allograft recipients with de novo proteinuria.
5. Urinary spot albumin:creatinine ratio for documenting proteinuria in women with preeclampsia.
6. Correlation between glomerular filtration rate and urinary N acetyl-beta-D glucosaminidase in children with persistent proteinuria in chronic glomerular disease.
7. Effect of submaximal aerobic exercise in hypoxic conditions on proteinuria and hematuria in physically trained young men.
8. Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort.
9. ACE Inhibition in Anti-Thy1 Glomerulonephritis Limits Proteinuria but Does Not Improve Renal Function and Structural Remodeling.
10. Urinary protein/creatinine ratio versus 24-hour proteinuria in the evaluation of lupus nephritis.
11. Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model.
12. Interstitial nephritis with moderate-to-heavy proteinuria: an unusual combination.
13. Determining the prevalence of human immunodeficiency virus-associated nephropathy (HIVAN) using proteinuria and ultrasound findings in a Nigerian paediatric HIV population.
14. Proteinuria: an ignored marker of inflammation and cardiovascular disease in chronic hemodialysis.
15. Short-Term Calorie Restriction in Early Life Attenuates the Development of Proteinuria but Not Glucose Intolerance in Type 2 Diabetic OLETF Rats.
16. Preoperative proteinuria is associated with long-term progression to chronic dialysis and mortality after coronary artery bypass grafting surgery.
17. Massive proteinuria and autosomal dominant polycystic kidney disease: a rare coincidence.
18. Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus.
19. Sex dimorphism in serum lecithin: cholesterol acyltransferase and lipoprotein lipase activities in adult sickle cell anaemia patients with proteinuria.
20. Truncus arteriosus: A major cause of proteinuria in children.
21. Vesicoureteral Reflux, a Scarred kidney, and Minimal Proteinuria: An Unusual Cause of Adult Secondary Hypertension.
22. Preoperative proteinuria predicts acute kidney injury in patients undergoing cardiac surgery.
23. Nephrotic proteinuria and renal involvement in HIV-infected children.
24. Neuroblastoma presenting with acute kidney injury, hyponatremic-hypertensive-like syndrome and nephrotic proteinuria in a 10-month-old child.
25. A dipstick test combined with urine specific gravity improved the accuracy of proteinuria determination in pregnancy screening.
26. Chyluria associated with nephrotic-range proteinuria: pathophysiology, clinical picture and therapeutic options.
27. No evidence for statin-induced proteinuria in healthy volunteers as assessed by proteomic analysis.
28. Rosuvastatin prevents proteinuria and renal inflammation in nitric oxide-deficient rats.
29. Could peak proteinuria determine whether patient with dengue fever develop dengue hemorrhagic/dengue shock syndrome?--a prospective cohort study.
30. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.
31. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.
32. Relationships of risk factors for pre-eclampsia with patterns of occurrence of isolated gestational proteinuria during normal term pregnancy.
33. Consensus document. Recommendations on assessing proteinuria during the diagnosis and follow-up of chronic kidney disease.
34. Proteinuria in an African HIV-infected patient: effects of telmisartan.
35. Causes and consequences of proteinuria following kidney transplantation.
36. Nephroquiz 6: a 67-year-old kidney transplant recipient with nephrotic-range proteinuria.
37. Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy.
38. REIN on obesity, proteinuria and CKD.
39. Laboratory measurement of urine albumin and urine total protein in screening for proteinuria in chronic kidney disease.
40. Global proteinuria guidelines: are we nearly there yet?
41. ACE inhibition is renoprotective among obese patients with proteinuria.
42. Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes.
43. Adiponectin reduces proteinuria in streptozotocin-induced diabetic Wistar rats.
44. Ubiquitin C-terminal hydrolase-l1 activity induces polyubiquitin accumulation in podocytes and increases proteinuria in rat membranous nephropathy.
45. A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria.
46. Intrauterine growth restriction is associated with persistent aortic wall thickening and glomerular proteinuria during infancy.
47. The relation between estimated glomerular filtration rate and proteinuria in Okayama Prefecture, Japan.
48. Tubular proteinuria in mice and humans lacking the intrinsic lysosomal protein SCARB2/Limp-2.
49. Effects of Moderate-to-Severe Impairment of the Estimated Glomerular Filtration Rate and of Proteinuria on the Central Hemodynamics and Arterial Stiffness in Middle-Aged Healthy Japanese Men.
50. Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: is there light at the end of the tunnel?
51. Orthostatic proteinuria: a harmless variant of protein loss?
52. Luminal alkalinization attenuates proteinuria-induced oxidative damage in proximal tubular cells.
53. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease.
54. Association between arsenic exposure from drinking water and proteinuria: results from the Health Effects of Arsenic Longitudinal Study.
55. Proteinuria among adult sickle cell anemia patients in Nigeria.
56. Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS).
57. Effects of Qufengtongluo recipe on proteinuria and glomerular filtration membrane in rats with adriamycin-induced nephropathy.
58. Proteinuria.
59. Influence of proteinuria on glycated albumin values in diabetic patients with chronic kidney disease.
60. Glomerular podocytes express type 1 adenylate cyclase: inactivation results in susceptibility to proteinuria.
61. Proteinuria thresholds are irrational: a call for proteinuria indexing.
62. Effect of shen-qi-di-huang decoction on reducing proteinuria by preserving nephrin in adriamycin-induced nephropathy rats.
63. Effects of tridocosahexaenoyl-glycerol emulsion on proteinuria in rats with nephrotoxic serum nephritis.
64. Role of the podocyte in proteinuria.
65. Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats.
66. Endothelial surface layer degradation by chronic hyaluronidase infusion induces proteinuria in apolipoprotein E-deficient mice.
67. Kidney Dendritic Cells Become Pathogenic during Crescentic Glomerulonephritis with Proteinuria.
68. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome.
69. Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs).
70. Proteinuria among primarily sirolimus treated live-donor renal transplant recipients' long-term experience.
71. Preoperative proteinuria predicts adverse renal outcomes after coronary artery bypass grafting.
72. Absence of hypoalbuminemia despite nephrotic proteinuria in focal segmental glomerulosclerosis secondary to polycythemia vera.
73. Proteinuria in diabetes: bystander or pathway to cardiorenal disease?
74. Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury.
75. A molecular signature of proteinuria in glomerulonephritis.
76. Findings of renal biopsy in lupus patients with low levels of proteinuria.
77. Angiotensin-(1-7) reduces proteinuria and diminishes structural damage in renal tissue of stroke-prone spontaneously hypertensive rats.
78. Molecular mechanism of proteinuria caused progression of chronic renal disease.
79. Geno-transcriptomic dissection of proteinuria in the uninephrectomized rat uncovers a molecular complexity with sexual dimorphism.
80. Proteinuria induced by parenteral iron in chronic kidney disease--a comparative randomized controlled trial.
81. Effect of cyclosporin A on proteinuria in the course of glomerulopathy associated with WT1 mutations.
82. Proteinuria in children.
83. Proteinuria in children.
84. Cofilin-1 inactivation leads to proteinuria--studies in zebrafish, mice and humans.
85. High-calorie diet with moderate protein restriction prevents cachexia and ameliorates oxidative stress, inflammation and proteinuria in experimental chronic kidney disease.
86. Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset.
87. Protein-to-creatinine ratio: a valid estimate and alternative to 24 hour proteinuria.
88. Proteinuria in adult Saudi patients with sickle cell disease is not associated with identifiable risk factors.
89. Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun?
90. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
91. HIV and proteinuria in an injection drug user population.
92. Prevalence and prognostic significance of renal artery calcification in patients with diabetes and proteinuria.
93. Effects of admission serum urea, glomerular filtration rate, proteinuria and diabetes status on 3-month mortality after acute stroke.
94. Association between urinary type IV collagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria.
95. Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats.
96. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.
97. Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer.
98. Proteinuria among renal transplant patients and its relation to hepatitis C virus and graft outcome: a single center experience.
99. Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort.
100. Bevacizumab increases risk for severe proteinuria in cancer patients.
101. Deletion of von Hippel-Lindau in glomerular podocytes results in glomerular basement membrane thickening, ectopic subepithelial deposition of collagen {alpha}1{alpha}2{alpha}1(IV), expression of neuroglobin, and proteinuria.
102. Inhibition of podocyte FAK protects against proteinuria and foot process effacement.
103. Melanocortin 1 receptor agonists reduce proteinuria.
104. Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria.
105. New ways of thinking about proteinuria and progression of renal damage.
106. Obesity-related glomerulopathy: body mass index and proteinuria.
107. Podocyte number predicts progression of proteinuria in IgA nephropathy.
108. c-mip impairs podocyte proximal signaling and induces heavy proteinuria.
109. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.
110. An unusual cause for post-renal transplant hematuria and proteinuria: a retained double-J catheter.
111. Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.
112. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients.
113. PKC-delta promotes renal tubular cell apoptosis associated with proteinuria.
114. Relation between kidney function, proteinuria, and adverse outcomes--a critical look at the application of medical statistics in the Nephrology literature.
115. Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria.
116. Inflammatory and endothelial dysfunction markers and proteinuria in persons with type 1 diabetes mellitus.
117. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
118. Evaluation of glomerular filtration rate and of albuminuria/proteinuria.
119. Conversion of cyclosporine to sirolimus before 12 months is associated with marked improvement in renal function and low proteinuria in a South African renal transplant population.
120. A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes.
121. Citric acid inhibits development of cataracts, proteinuria and ketosis in streptozotocin (type 1) diabetic rats.
122. Randomized, double-blind, controlled study of losartan in children with proteinuria.
123. Case 5: 50-year-old woman with restrictive cardiomyopathy, renal failure and proteinuria.
124. Microalbuminuria predicts overt proteinuria among patients with HIV infection.
125. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.
126. Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.
127. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts.
128. Expression of nephrin, podocin and a-actinine-4 in renal tissue of patients with proteinuria.
129. Increase in proteinuria >200 mg/g after late rejection is associated with poor graft survival.
130. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
131. Letter by Barrios et al regarding article, "Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study".
132. Low rate of proteinuria in children after exposure to low-dose melamine: no predicted false positivity due to melamine.
133. alpha- and beta-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy.
134. Bariatric surgery for obese patients with proteinuria.
135. Rash, fever and proteinuria after amoxicillin in a SLE patient.
136. Significance and management of proteinuria in kidney transplant recipients.
137. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
138. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria.
139. Outcome of pregnancy in patients with inactive systemic lupus erythromatosus and minimal proteinuria.
140. Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients.
141. Proteinuria in cystic fibrosis: a possible correlation between genotype and renal phenotype.
142. Nephrotic-range proteinuria in a patient with primary antiphospholipid syndrome.
143. Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat.
144. Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects.
145. GEC-targeted HO-1 expression reduces proteinuria in glomerular immune injury.
146. Thyroid function in patients with proteinuria.
147. The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era.
148. Lithium poisoning and proteinuria in the nephrotic range.
149. Hypercoagulability in a patient with chronic chyluria, proteinuria and hypoalbuminaemia.
150. Remission of proteinuria with treatment of Actinomyces infection: eradicating a cause of secondary membranous glomerulopathy suppresses nephrotic syndrome.
151. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease.
152. Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD.
153. Telmisartan did not prevent renal disease in patients without proteinuria.
154. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.
155. Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure.
156. Comparison of 24-hour urinary protein and protein-to-creatinine ratio in the assessment of proteinuria.
157. Proteinuria in urinary infection and acute pyelonephritis in paediatric patients: can it replace scintigraphic studies in diagnostic localisation?.
158. Clinico-pathological correlations in 127 patients in 11 large pedigrees, segregating one of three heterozygous mutations in the COL4A3/ COL4A4 genes associated with familial haematuria and significant late progression to proteinuria and chronic kidney disease from focal segmental glomerulosclerosis.
159. Proteinuria: not a small problem in the little ones.
160. Proteinuria as a predictor of complications of pre-eclampsia.
161. Estimation of proteinuria as a predictor of complications of pre-eclampsia: a systematic review.
162. Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study.
163. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.
164. GFR, proteinuria and circadian blood pressure.
165. Proteinuria and epithelial-to-mesenchymal transition: the role of complement.
166. A 21-year-old pregnant woman with hypertension and proteinuria.
167. Reduction of proteinuria in adriamycin-induced nephropathy is associated with reduction of renal kidney injury molecule (Kim-1) over time.
168. Prevalence of low glomerular filtration rate, proteinuria and associated risk factors in North India using Cockcroft-Gault and Modification of Diet in Renal Disease equation: an observational, cross-sectional study.
169. Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria.
170. Minimal proteinuria one year after transplant is a risk factor for graft survival in kidney transplantation.
171. Proteinuria as a predictor of renal functional outcome after revascularization in atherosclerotic renovascular disease (ARVD).
172. Investigating the effect of genetic background on proteinuria and renal injury using two hypertensive strains.
173. Circulating angiogenic factors in gestational proteinuria without hypertension.
174. 25-year-old man with flank pain, hematuria, and proteinuria.
175. How do aldosterone blockers associated with ACE inhibitors or ARBs affect proteinuria in patients with chronic kidney disease?.
176. Therapeutic effect of Tripterygium wilfordii multiglycosides on proteinuria in kidney transplant recipients.
177. Thyroid function in patients with proteinuria.
178. Adriamycin alters glomerular endothelium to induce proteinuria.
179. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats.
180. Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients.
181. Management and control of hypertension and proteinuria in patients with advanced chronic kidney disease under nephrologist care or not: data from the AVENIR study (AVantagE de la Nephroprotection dans l'Insuffisance Renale).
182. Primary care approach to proteinuria.
183. Use of a first-line urine protein-to-creatinine ratio strip test on random urines to rule out proteinuria in patients with chronic kidney disease.
184. Proteinuria in mice expressing PKB/SGK-resistant GSK3.
185. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis.
186. Efficacy of deoxyspergualine for antibody-mediated rejection and proteinuria after kidney transplantation.
187. Nephrotic range proteinuria in c-ANCA-positive crescentic glomerulonephritis with linear immune deposits.
188. Determination of urinary peptides in patients with proteinuria.
189. Gross proteinuria is a strong risk predictor for cardiovascular mortality in Brazilian type 2 diabetic patients.
190. Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene.
191. Are optimal doses of benazepril and losartan to reduce proteinuria more nephroprotective than conventional doses in non-diabetic proteinuric nephropathies?.
192. Proteinuria and hyperglycemia induce endoplasmic reticulum stress.
193. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis.
194. Taurine administration after appearance of proteinuria retards progression of diabetic nephropathy in rats.
195. Use of urine albumin/creatinine ratio for estimation of proteinuria in cats and dogs.
196. Megalin contributes to the early injury of proximal tubule cells during nonselective proteinuria.
197. Treatment with pyrrolidine dithiocarbamate improves proteinuria, oxidative stress, and glomerular hypertension in overload proteinuria.
198. Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy.
199. Nephron deficit is not required for progressive proteinuria development in the Munich Wistar Frömter rat.
200. Selective loss of podoplanin protein expression accompanies proteinuria and precedes alterations in podocyte morphology in a spontaneous proteinuric rat model.
201. Risk factors for proteinuria in HIV-infected and -uninfected Hispanic drug users.
202. Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies.
203. Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome).
204. Relationship between albuminuria and total proteinuria in systemic lupus erythematosus nephritis: diagnostic and therapeutic implications.
205. Linking adiponectin to proteinuria.
206. Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review.
207. Assessment of proteinuria in pregnancy.
208. Properties of the glomerular barrier and mechanisms of proteinuria.
209. Urinalysis vs urine protein-creatinine ratio to predict significant proteinuria in pregnancy.
210. Diagnostic accuracy of the protein/creatinine ratio in urine samples to estimate 24-h proteinuria in patients with primary glomerulopathies: a longitudinal study.
211. A case of polyneuropathy and proteinuria.
212. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
213. Chronic tempol prevents hypertension, proteinuria, and poor feto-placental outcomes in BPH/5 mouse model of preeclampsia.
214. Potential sources of oxidative stress that induce postexercise proteinuria in rats.
215. Slowing nephropathy progression: focus on proteinuria reduction.
216. Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease.
217. Post-renal transplant proteinuria: the saudi experience.
218. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria.
219. ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction.
220. Excessive fluid intake as a novel cause of proteinuria.
221. Peritubular ischemia contributes more to tubular damage than proteinuria in immune-mediated glomerulonephritis.
222. Melatonin ameliorates oxidative stress, inflammation, proteinuria, and progression of renal damage in rats with renal mass reduction.
223. A spoonful of sugar helps the proteinuria go down?
224. Distribution of pathologic findings in individuals with nephrotic proteinuria according to serum albumin.
225. Proteinuria in children with sickle cell disease.
226. Proteinuria as a predictor of risk of cardiovascular disease: a new insight.
227. Evaluation of hematuria and proteinuria positivity in relation to ageing in 6,651 apparently healthy men and women.
228. Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria.
229. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.
230. Proteinuria in a boy with infectious mononucleosis, C1q nephropathy, and Dent's disease.
231. Remission of proteinuria improves prognosis in IgA nephropathy.
232. Prevalence of persistent proteinuria in stable HIV/AIDS patients and its association with HIV nephropathy.
233. Nephrotic proteinuria and the autonomic nervous system.
234. Interferon-beta reduces proteinuria in experimental glomerulonephritis.
235. Proteinuria after kidney transplantation: its relation to hepatitis C virus and graft outcome.
236. Marked reduction of proteinuria after eradication of gastric Helicobacter pylori infection in a patient with membranous nephropathy: coincidental or associated?
237. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass.
238. Aldosterone receptor antagonism alleviates proteinuria, but not malignant hypertension, in Cyp1a1-Ren2 transgenic rats.
239. Proteinuria and endothelial dysfunction in stable HIV-infected patients. A pilot study.
240. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system.
241. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
242. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors.
243. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
244. Proteinuria: is it all in the foot?
245. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
246. Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia.
247. Angiopoietin-2 and glomerular proteinuria.
248. Proteinuria lowers the risk of amphotericin B-associated hypokalaemia.
249. Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53:Mena signaling complexes in kidney podocytes.
250. Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine.
251. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.
252. High-protein diet and high-grade proteinuria aggravate the progression of chronic renal failure in rats.
253. Proteinuria increases oxylipid concentrations in VLDL and HDL but not LDL particles in the rat.
254. Is proteinuria reduction by angiotensin-converting enzyme inhibition enough to prove its role in renal protection in IgA nephropathy?
255. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols.
256. Response of HIV-associated proteinuria to antiretroviral therapy in HIV-1-infected children.
257. Treating proteinuria in a diabetic patient despite hyperkalaemia due to hyporeninaemic hypoaldosteronism.
258. Giant bilateral perinephric tumour and overt proteinuria.
259. A cutaneous disease with multisystem involvement: hypomelanosis of Ito may be associated with proteinuria, focal segmental glomerulosclerosis and end-stage renal disease.
260. In vivo degradation of heparan sulfates in the glomerular basement membrane does not result in proteinuria.
261. J Am Soc Nephrol. 2007 Mar;18(3):823-32. Epub 2007 Jan 24. Retraction in: J Am Soc Nephrol. 2008 Mar;19(3):647.
262. Absence of increased alpha1-microglobulin in IgA nephropathy proteinuria.
263. Development of overt proteinuria in the Munich Wistar Frömter rat is suppressed by replacement of chromosome 6 in a consomic rat strain.
264. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria.
265. High iron stores and the relationship between metabolic syndrome and proteinuria.
266. Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis.
267. How does proteinuria cause progressive renal damage?
268. Prevalence of proteinuria in rural adult population in Tamil Nadu.
269. Nephrotic-range proteinuria in the obese patient.
270. Severe feto-placental abnormalities precede the onset of hypertension and proteinuria in a mouse model of preeclampsia.
271. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
272. Acute renal failure during lisinopril and losartan therapy for proteinuria.
273. Gross proteinuria post transplant in a child with nephrotic syndrome of the Finnish type--mechanical vs immunological pathogenesis.
274. Renal and cardiovascular effects of angiotensin-converting enzyme inhibitor plus angiotensin II receptor antagonist therapy in children with proteinuria.
275. Proteinuria with and without renal glomerular podocyte effacement.
276. Proteinuria precedes podocyte abnormalities inLamb2-/- mice, implicating the glomerular basement membrane as an albumin barrier.
277. Proteinuria, pancytopenia and hypoxaemic respiratory failure in a 28-year-old female.
278. Does urinary tract infection cause proteinuria or microalbuminuria? A systematic review.
279. Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes.
280. Role of the kidney in the metabolism of apolipoprotein A-IV: influence of the type of proteinuria.
281. Proteinuria, renal impairment, and death.
282. Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria.
283. Relationship between metabolic syndrome and proteinuria in the Japanese population.
284. Imerslund-Gräsbeck syndrome (selective vitamin B(12) malabsorption with proteinuria).
285. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial.
286. Pathologic features and prognosis of 21 children with isolated proteinuria.
287. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment.
288. Effect of nitric oxide synthase inhibition on proteinuria in glomerular immune injury.
289. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial.
290. Glomerulotubular junction abnormalities are associated with proteinuria in type 1 diabetes.
291. Massive increase in proteinuria after the introduction of midodrine in an elderly patient-a case report.
292. Proteinuria in chronic renal disease was not mentioned.
293. Proteinuria.
294. Genetic dissection of proteinuria in the Sabra rat.
295. Urinary excretions of lipocalin-type prostaglandin D2 synthase predict the development of proteinuria and renal injury in OLETF rats.
296. The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice.
297. In mice, proteinuria and renal inflammatory responses to albumin overload are strain-dependent.
298. Proteinuria--CARI guidelines.
299. Post-transplantation proteinuria and sirolimus.
300. Grafted kidney, native kidney and proteinuria after pre-emptive pancreas-kidney transplantation: questions and answers.
301. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria.
302. Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension.
303. Alpha-galactosidase activity should be examined in patients with proteinuria: what have we learned from a family affected with Fabry disease?
304. Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy.
305. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria.
306. Proteinuria is a prognostic marker for cardiovascular mortality: NIPPON DATA 80, 1980-1999.
307. Orthostatic proteinuria or latent nephritis?.
308. Chromosomes 18 and X are quantitative trait loci for nephrotic-range proteinuria in rats.
309. Proteinuria as a determinant of renal expression of heme oxygenase-1: studies in models of glomerular and tubular proteinuria in the rat.
310. Proteinuria: a link to understanding changes in vascular compliance?
311. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy.
312. Insulin resistance contributes to obesity-related proteinuria.
313. Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review.
314. A case of cranial venous sinus thrombosis and proteinuria.
315. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome.
316. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients.
317. Renal accumulation of pentosidine in non-diabetic proteinuria-induced renal damage in rats.
318. Prevalence of chronic kidney disease based on estimated glomerular filtration rate and proteinuria in Icelandic adults.
319. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.
320. Sam68-like mammalian protein 2, identified by digital differential display as expressed by podocytes, is induced in proteinuria and involved in splice site selection of vascular endothelial growth factor.
321. Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis.
322. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.
323. Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
324. Detection and localization of proteinuria by dynamic contrast-enhanced magnetic resonance imaging using MS325.
325. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria.
326. Graded effects of proteinuria on HDL structure in nephrotic rats.
327. RF-2 gene modulates proteinuria and albuminuria independently of changes in glomerular permeability in the fawn-hooded hypertensive rat.
328. Diabetic nephropathy: the proteinuria hypothesis.
329. Retarding the progression of diabetic nephropathy in type 2 diabetes mellitus: focus on hypertension and proteinuria.
330. Effects of sodium restriction and cyclooxygenase-2 inhibition on the course of hypertension, proteinuria and cardiac hypertrophy in Ren-2 transgenic rats.
331. Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein.
332. 49, XXXXY syndrome with unilateral renal aplasia, proteinuria, and venous thromboembolism.
333. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study.
334. Treatment of unilateral obstruction reversing heavy and bilateral proteinuria.
335. Induction of renal tubular cell apoptosis in focal segmental glomerulosclerosis: roles of proteinuria and Fas-dependent pathways.
336. Hypoxia in renal disease with proteinuria and/or glomerular hypertension.
337. Progression of renal failure without proteinuria in a patient with type 1 diabetes.
338. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition.
339. A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis.
340. Association between cigarette consumption and proteinuria in healthy Japanese men and women from an occupational population.
341. On the nature of proteinuria with acute renal injury in patients with chronic kidney disease.
342. Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuria.
343. Podocytes are firmly attached to glomerular basement membrane in kidneys with heavy proteinuria.
344. Clinical practice guidelines for chronic kidney disease in adults: Part II. Glomerular filtration rate, proteinuria, and other markers.
345. Patterns of proteinuria: urinary sodium dodecyl sulfate electrophoresis versus immunonephelometric protein marker measurement followed by interpretation with the knowledge-based system MDI-LabLink.
346. Effects of angiotensin II receptor blocker on proteinuria in renal transplant recipients.
347. Statin induced proteinuria: renal injury or renoprotection?
348. Study of the mechanism of preventing proteinuria by Yishen Gujing Decoction (YSGJD) in early diabetic nephropathy.
349. Serum ferritin levels are increased in patients with glomerular diseases and proteinuria.
350. A "pulseless" woman with proteinuria!.
351. Proteinuria in hypertensive syndrome of pregnancy: maternal and perinatal outcome.
352. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
353. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases.
354. Effect of chronic tetrahydrobiopterin supplementation on blood pressure and proteinuria in 5/6 nephrectomized rats.
355. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
356. Urinary excretion of advanced glycation endproducts in patients with type 2 diabetes and various stages of proteinuria.
357. Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation.
358. Predicting of histopathological grade of chronic allograft nephropathy from renal function and proteinuria.
359. Persistent proteinuria up-regulates angiotensin II type 2 receptor and induces apoptosis in proximal tubular cells.
360. Case report: Response in proteinuria due to AA amyloidosis but not Felty's syndrome in a patient with rheumatoid arthritis treated with TNF-alpha blockade.
361. Relationship between podocyte molecule's distribution and expression, foot process morphology and proteinuria.
362. Regarding: "Management of glomerular proteinuria: a commentary".
363. Could proteinuria evaluation be helpful in predicting renal progression in apolipoprotein E-deficient (E-/-) mice with chronic renal failure?
364. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients.
365. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes.
366. Lymphadenopathy and proteinuria.
367. Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier.
368. Nephrotic range proteinuria in a renal transplant associated with oncocytoma of the native kidney.
369. Proteinuria after renal transplantation: pathogenesis and management.
370. Proteinuria and interstitial injury.
371. Proteinuria and hypertension are independent factors affecting fetal DNA values: a retrospective analysis of affected and unaffected patients.
372. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis.
373. Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis.
374. Retinal vessel diameters and the incidence of gross proteinuria and renal insufficiency in people with type 1 diabetes.
375. Protein/creatinine ratio in single urine samples for the semiquantitation of proteinuria in children with nephrosis
376. Angiotensin II-induced proteinuria and expression of the podocyte slit pore membrane protein, nephrin.
377. Lipid management in the proteinuric patient: do not overlook the importance of proteinuria reduction.
378. Management of glomerular proteinuria: a commentary.
379. DNA vaccination against specific pathogenic TCRs reduces proteinuria in active Heymann nephritis by inducing specific autoantibodies.
380. Association between albuminuria and proteinuria in the general population: the AusDiab Study.
381. Effect of nitric oxide on exercise-induced proteinuria in rats.
382. Proteinuria: how to evaluate an important finding.
383. On testing for proteinuria: time for a methodical approach.
384. Milk or albumin? The history of proteinuria before Richard Bright.
385. Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria.
386. Proteinuria and phenotypic change of proximal tubular cells.
387. Podocyte differentiation and hereditary proteinuria/nephrotic syndromes.
388. Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.
389. Effects of short-term transdermal hormone replacement therapy on glycaemic control, lipid metabolism, C-reactive protein and proteinuria in postmenopausal women with type 2 diabetes or hypertension.
390. Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis.
391. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
392. The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients.
393. Regular low-intensity aquatic exercise improves cardio-respiratory functional capacity and reduces proteinuria in chronic renal failure patients.
394. Glomerular immune deposits are associated with increased proteinuria in patients with ANCA-associated crescentic nephritis.
395. Proteinuria in COPD patients with and without respiratory failure.
396. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria.
397. Transforming growth factor-beta(1) in the kidney and urine of patients with glomerular disease and proteinuria.
398. Protein-creatinine ratio--a simple method for proteinuria assessment in clinical practice.
399. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab.
400. Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells.
401. Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria.
402. Effects of benidipine on glomerular hemodynamics and proteinuria in patients with nondiabetic nephropathy.
403. Fatty acids exacerbate tubulointerstitial injury in protein-overload proteinuria.
404. Endothelin receptor A blockade reduces proteinuria and vascular hypertrophy in spontaneously hypertensive rats on high-salt diet in a blood-pressure-independent manner.
405. Dual renin-angiotensin system blockade at optimal doses for proteinuria.
406. Influence of smoking and obesity on the development of proteinuria.
407. Contribution of Paul Govaerts (1889-1960) to the understanding of oedema and proteinuria. The essential role of physiological knowledge in clinical medicine.
408. Cadmium and lead in blood in relation to low bone mineral density and tubular proteinuria.
409. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy.
410. Effect of pravastatin on proteinuria in patients with well-controlled hypertension.
411. Risk factors for proteinuria in a large, multiracial, southeast Asian population.
412. Light chain proteinuria and lysozymuria in a patient with acute monocytic leukemia.
413. Proteinuria and glomerulosclerosis in the Sabra genetic rat model of salt susceptibility.
414. Novel concepts in understanding and management of glomerular proteinuria.
415. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis.
416. Do severe systemic sequelae of proteinuria modulate the antiproteinuric response to chronic ACE inhibition?
417. Proteinuria is preceded by decreased nitric oxide synthesis and prevented by a NO donor in cholesterol-fed rats.
418. Gene expression profile of renal proximal tubules regulated by proteinuria.
419. Proteinuria in obstructive sleep apnea.
420. FK506 ameliorates proteinuria and glomerular lesions induced by anti-Thy 1.1 monoclonal antibody 1-22-3.
421. Smoking and proteinuria impair vasodilatory response of intrarenal arteries to nitroglycerine in patients with type 2 diabetes mellitus.
422. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria.
423. Nephrology: 2. Evaluation of asymptomatic hematuria and proteinuria in adult primary care.
424. Renal function, proteinuria and ACE-inhibitor therapy as determinants of plasma levels of endothelial markers.
425. Focal segmental glomerulosclerosis, proteinuria and nephrocalcinosis associated with renal tubular acidosis.
426. Predictors of proteinuria and renal failure among women with HIV infection.
427. Patterns of nephrin and a new proteinuria-associated protein expression in human renal diseases.
428. Biological analysis of proteinuria in the laboratory: quantitative features.
429. Proteinuria and tubulointerstitial lesions in lupus nephritis.
430. Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1.
431. Long-term effect of angiotensin-converting inhibitors in children with proteinuria.
432. Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria.
433. Relationship between anti-insulin antibodies and albuminuria or proteinuria in human insulin-treated type 2 diabetes mellitus.
434. Proteinuria in obstructive sleep apnea.
435. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.
436. Il-4 therapy prevents the development of proteinuria in active Heymann nephritis by inhibition of Tc1 cells.
437. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.
438. Heterogeneity of prognosis in adult IgA nephropathy, especially with mild proteinuria or mild histological features.
439. Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis.
440. Integrin-linked kinase as a candidate downstream effector in proteinuria.
441. Diagnosis of nut-cracker phenomenon using renal Doppler ultrasound in orthostatic proteinuria.
442. Diabetic nephropathy: an epidemiological study based on proteinuria in a population of black African diabetics in Cotonou, Benin.
443. High proteinuria selectivity index based upon IgM is a strong predictor of poor renal survival in glomerular diseases.
444. Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN.
445. Tryptophan immunoadsorption strongly reduces proteinuria in recurrent nephrotic syndrome.
446. Partial lipodystrophy, polycystic ovary syndrome and proteinuria: a common link to insulin resistance?
447. Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome.
448. Rapid and diverse changes of gene expression in the kidneys of protein-overload proteinuria mice detected by microarray analysis.
449. Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1.
450. Selectivity of proteinuria can be estimated reliably from samples of second-morning urine.
451. Plasma protein synthesis in patients with low-grade nephrotic proteinuria.
452. Adult height and proteinuria in type 2 diabetes.
453. Focal segmental glomerulosclerosis: unremitting proteinuria of long duration as a possible etiology?
454. An endocytosis defect as a possible cause of proteinuria in polycystic kidney disease.
455. The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death.
456. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome.
457. Effect of plasma fractions from patients with focal and segmental glomerulosclerosis on rat proteinuria.
458. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis.
459. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy.
460. F(2)-isoprostanes mediate high glucose-induced TGF-beta synthesis and glomerular proteinuria in experimental type I diabetes.
461. A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome.
462. Proteinuria in adults: a diagnostic approach.
463. Male gender increases sensitivity to proteinuria induced by mild NOS inhibition in rats: role of sex hormones.
464. Proteinuria in the transplanted patient.
465. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population.
466. Patients with nephrotic-range proteinuria have apolipoprotein C and E deficient VLDL1.
467. Primary antiphospholipid syndrome presenting with cerebral ischemia, thrombocytopenia, anemia and proteinuria successfully treated with warfarin potassium.
468. Frequency of proteinuria in type 2 diabetes mellitus seen at a diabetes centre in southern India.
469. Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective.
470. Clinicopathologic Session. (Case 1/00--a 65-year-old woman with heart failure and proteinuria - Instituto do Coracao do Hospital das Clínicas-FMUSP.
471. An anti-CD5 monoclonal antibody ameliorates proteinuria and glomerular lesions in rat mesangioproliferative glomerulonephritis.
472. Increased spontaneous adherence of neutrophils from type 2 diabetic patients with overt proteinuria: possible role of the progression of diabetic nephropathy.
473. Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction.
474. Trends in persistent proteinuria in adult-onset diabetes: a population-based study.
475. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus.
476. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats.
477. Rapid remission of nephrotic-range proteinuria in a case of histologically proven diabetic nephropathy treated with an ACE inhibitor.
478. Massive proteinuria in a patient with chronic pyelonephritis.
479. Severe proteinuria, sustained for 6 months, induces tubular epithelial cell injury and cell infiltration in rats but not progressive interstitial fibrosis.
480. Clinical significance and evaluation of proteinuria in NIDDM patients.
481. Proximal tubular epithelial hyperplasia in patients with chronic glomerular proteinuria.
482. Induction of experimental proteinuria in vivo following infusion of human plasma hemopexin.
483. A man with proteinuria, familial history of kidney disease, painful extremities and cutaneous lesions.
484. Racial group, socioeconomic status, and the development of persistent proteinuria in systemic lupus erythematosus.
485. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria.
486. Proteinuria in atherosclerotic renovascular disease.
487. Tubular proteinuria defined by a study of Dent's (CLCN5 mutation) and other tubular diseases.
488. Progression of microalbuminuria to proteinuria in type 1 diabetes: nonlinear relationship with hyperglycemia.
489. We need to inhibit complement in glomerular proteinuria.
490. Crry, a complement regulatory protein, modulates renal interstitial disease induced by proteinuria.
491. Heme oxygenase-1 induction attenuates inducible nitric oxide synthase expression and proteinuria in glomerulonephritis.
492. Systemic factors are involved in the pathogenesis of proteinuria-induced glomerulosclerosis in adriamycin nephrotic rats.
493. Ischaemic nephropathy-is the diagnosis excluded by heavy proteinuria?
494. Megalin knockout mice as an animal model of low molecular weight proteinuria.
495. Edmund Randerath (1899-1961): experimental proof for the glomerular origin of proteinuria.
496. Proteinuria is an independent risk factor for ischemic stroke in non-insulin-dependent diabetes mellitus.
497. Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure.
498. Antibody induced injury to podocytes with proteinuria and foot process swelling in a transgenic (T16) mouse.
499. Blood pressure reduction is necessary for the reduction of proteinuria in diabetic nephropathy--comparison of different antihypertensive agents.
500. High serum IgE levels are associated with selective proteinuria in glomerulonephritis.
501. MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis.
502. Effect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus type 2.
503. HBV and proteinuria in relatives and contacts of children with hepatitis B virus-associated membranous nephropathy.
504. Glomerular and tubular proteinuria as markers of nephropathy in rheumatoid arthritis.
505. Pseudo-proteinuria following gelofusine infusion.
506. Orthostatic proteinuria as a result of venous compression (nutcracker phenomenon)--a hypothesis testable with modern imaging techniques.
507. Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy.
508. Residual proteinuria in CAPD diminishes the value of serum albumin in audit.
509. Deletion polymorphism of the angiotensin converting enzyme gene predicts persistent proteinuria in Henoch-Schönlein purpura nephritis.
510. Proteinuria is associated with persistence of antibody to streptococcal M protein in Aboriginal Australians.
511. Relationship between glycosylated hemoglobin and the prevalence of proteinuria in Japanese men.
512. The young lady with massive proteinuria, biopsy-confirmed steroid-resistant minimal change glomerulonephritis and episodes of turbid urine.
513. Proteinuria induces tubular cell turnover: A potential mechanism for tubular atrophy.
514. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
515. Angiotensin-converting enzyme is upregulated in the proximal tubules of rats with intense proteinuria.
516. Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema, and proteinuria in stroke-prone hypertensive rats.
517. Chloride channel CLCN5 mutations in Japanese children with familial idiopathic low molecular weight proteinuria.
518. Proteinuria selectivity index based upon alpha 2-macroglobulin or IgM is superior to the IgG based index in differentiating glomerular diseases. Technical note.
519. An epidemic of proteinuria in Pima Indians with type 2 diabetes mellitus.
520. Determination of total proteinuria: a comparative study of automated trichloracetic acid and pyrogallol red techniques for samples with monoclonal light chains.
521. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension.
522. Effects of soy protein on renal function and proteinuria in patients with type 2 diabetes.
523. Acute nephrotoxic serum nephritis in complement knockout mice: relative roles of the classical and alternate pathways in neutrophil recruitment and proteinuria.
524. Proteinuria and damage to tubular cells--is complement a culprit?
525. Rapid progression to end-stage renal disease in young hypertensive African Americans with proteinuria.
526. Permanent CD8(+) T cell depletion prevents proteinuria in active Heymann nephritis.
527. Epitope-specific antibodies to the 43-kD glomerular membrane protein podoplanin cause proteinuria and rapid flattening of podocytes.
528. Evaluating proteinuria in children.
529. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
530. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy.
531. Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome.
532. Proteinuria, hypertension and chronic renal failure in X-linked Kallmann's syndrome, a defined genetic cause of solitary functioning kidney.
533. Increased atherogenicity of low-density lipoprotein in heavy proteinuria.
534. Anti-vitronectin antibodies enhance anti-Thy-1-induced proteinuria in PVG/c, but not in Wistar rats.
535. Mutations in CLCN5 chloride channel in Japanese patients with low molecular weight proteinuria.
536. Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria.
537. Proteinuria in a patient with the diaphragmatic hernia-hypertelorism-myopia-deafness syndrome: further evidence that the facio-oculo-acoustico-renal syndrome represents the same entity.
538. Heavy proteinuria, podocyte hypertrophy and severe systemic manifestations in a patient on phenytoin therapy.
539. Vesicoureteral reflux diagnosed in adulthood. Incidence of urinary tract infections, hypertension, proteinuria, back pain and renal calculi.
540. Proteinuria precedes cerebral edema in stroke-prone rats: a magnetic resonance imaging study.
541. A role for Mac-1 (CDIIb/CD18) in immune complex-stimulated neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fcgamma receptor-dependent neutrophil adhesion and complement-dependent proteinuria in acute glomerulonephritis.
542. Glomerulomegaly and proteinuria in a patient with idiopathic pulmonary hypertension.
543. The patient presenting with proteinuria and a history of brain tumour in childhood: is there a quietly lurking nephrological nemesis?
544. Platelet-activating factor mediates angiotensin II-induced proteinuria in isolated perfused rat kidney.
545. Reduced proteinuria after cessation of long-acting, osmotic release nifedipine GITS in diabetic nephropathy.
546. Proteinuria in healthy individuals over 75 years of age.
547. Proteinuria in a young man.
548. Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy.
549. A child with panniculitis and microhaematuria/proteinuria--an unusual presentation of p-ANCA-positive vasculitis.
550. Danaparoid sodium lowers proteinuria in diabetic nephropathy.
551. Idiopathic low molecular weight proteinuria associated with hypercalciuric nephrocalcinosis in Japanese children is due to mutations of the renal chloride channel (CLCN5).
552. Differential effects of sex hormones on autoantibody production and proteinuria in chronic graft-versus-host disease-induced experimental lupus nephritis.
553. Isolated glomerular proteinuria as the only clinical manifestation of Fabry's disease in an adult male.
554. Does torasemide reduce proteinuria in nephrotic patients?
555. Association between heparan sulfate proteoglycan excretion and proteinuria after renal transplantation.
556. Macrophage-colony stimulating factor (M-CSF) enhances proteinuria and recruitment of macrophages into the glomerulus in experimental murine nephritis.
557. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects.
558. The effects of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure.
559. Elastase, but not proteinase 3 (PR3), induces proteinuria associated with loss of glomerular basement membrane heparan sulphate after in vivo renal perfusion in rats.
560. Renovascular hypertension with massive proteinuria.
561. Bioactivity of glomerular ultrafiltrate during heavy proteinuria may contribute to renal tubulo-interstitial lesions: evidence for a role for insulin-like growth factor I.
562. Atrial natriuretic peptide, sodium retention, and proteinuria in nephrotic syndrome.
563. Adriamycin-induced proteinuria in nude mice: an immune-system-mediated toxic effect.
564. Glycosaminoglycans: a new paradigm in the prevention of proteinuria and progression of glomerular disease.
565. Doxazosin prevents proteinuria and glomerular loss of heparan sulfate in diabetic rats.
566. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group.
567. Bence Jones proteinuria and myeloma kidney.
568. Angiotensin-converting enzyme inhibition in experimental in-situ immune complex glomerulonephritis: influence on renal function, proteinuria, and morphology.
569. Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria.
570. Improvement of hyperlipidemia and proteinuria without noticeable growth retardation by feeding a methionine and threonine supplemented low-casein diet to nephritic rats.
571. Thrombolytic treatment and proteinuria.
572. Strain variation in susceptibility to the development of monoclonal antibody 5-1-6-induced proteinuria in rats.
573. S-(1,2-dichlorovinyl)-L-cysteine-induced nephrotoxicity in the New Zealand white rabbit: characterization of proteinuria and examination of the potential role of oxidative injury.
574. Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria.
575. Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria.
576. Reduction of hyperlipidemia and proteinuria without growth retardation in nephritic rats by a methionine-supplemented, low-soy-protein diet.
577. Danish general practitioners' estimation of urinary albumin concentration in the detection of proteinuria and microalbuminuria.
578. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease.
579. Electrophoretic study of the physico-chemical characteristics of Bence-Jones proteinuria and its association with kidney damage.
580. Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen.
581. Prevention of proteinuria by the administration of anti-interleukin 8 antibody in experimental acute immune complex-induced glomerulonephritis.
582. Alterations in glomerular anionic sites in canine anti-glomerular basement membrane nephritis with onset of severe proteinuria.
583. Antibodies to glycolipids activate complement and promote proteinuria in passive Heymann nephritis.
584. Proteinuria associated with glomerulosclerosis and glomerular collagen formation in three Newfoundland dog littermates.
585. Proteinuria induced by anti-dipeptidyl peptidase IV (gp108); role of circulating and glomerular antigen.
586. L-arginine administration prevents glomerular hyperfiltration and decreases proteinuria in diabetic rats.
587. Increased risk of proteinuria among a cohort of lead-exposed pregnant women.
588. Mechanisms of orthostatic proteinuria: lessons from a transplant donor.
589. Divalency of the monoclonal antibody 5-1-6 is required for induction of proteinuria in rats.
590. Quantitative study of mesangial injury with proteinuria induced by monoclonal antibody 1-22-3.
591. Beta 2-glycoprotein-1 (apolipoprotein H) excretion and renal tubular malfunction in diabetic patients without clinical proteinuria.
592. Leukotriene D4 is a mediator of proteinuria and glomerular hemodynamic abnormalities in passive Heymann nephritis.
593. Low-molecular-mass proteinuria as a marker of proximal renal tubular dysfunction in normo- and microalbuminuric non-insulin-dependent diabetic subjects.
594. Epitope specificity of anti-gp330 autoantibodies determines the development of proteinuria in active Heymann nephritis.
595. The progression of renal damage in reflux nephropathy--clinical analysis of proteinuria in children with vesicoureteral reflux.
596. Renal AA amyloidosis in a patient with Bence Jones proteinuria and ankylosing spondylitis.
597. Mesangial sclerotic change with persistent proteinuria in rats after two consecutive injections of monoclonal antibody 1-22-3.
598. Effect of captopril on heavy proteinuria in patients with various glomerular diseases.
599. Clinical studies of the prognosis in cases of chance proteinuria and/or hematuria.
600. Urine albumin, total protein, and glomerular proteinuria.
601. Epitope-specific induction of mesangial lesions with proteinuria by a MoAb against mesangial cell surface antigen.